There were 843 press releases posted in the last 24 hours and 442,485 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image